Hyperhidrosis is an idiopathic condition of exaggerated sweat production by the eccrine glands that affects approximately 1% of the population. There are many viable therapeutic options and the use of botulinum toxin ...Hyperhidrosis is an idiopathic condition of exaggerated sweat production by the eccrine glands that affects approximately 1% of the population. There are many viable therapeutic options and the use of botulinum toxin has become an important treatment option and received FDA approval for this disorder in July 2004. The other forms of aberrant sweating; bromhidrosis (malodorous) and chromhidrosis (pigmented) are much rarer and more recalcitrant to treatment. This is the first case report of dark-colored facial sweat in a young woman that was adequately controlled with botulinum toxin. Chromhidrosis is an unusual clinical entity with an ill defined glandular etiology. The successful response to botulinum toxin supports the eccrine gland as a source of the sweat production and, furthermore, that the administration of this toxin should be considered as a form of therapy.展开更多
Axillary hyperhydrosis in children and teenagers may be severe enough to affect social development. Current treatments range from aluminum chloride compounds to surgical removal of sweat glands and sympathectomy. Intr...Axillary hyperhydrosis in children and teenagers may be severe enough to affect social development. Current treatments range from aluminum chloride compounds to surgical removal of sweat glands and sympathectomy. Intradermal injection of botulinum A toxin has recently been found to be a safe and effective alternative in the adult population. Use in children has so far not been documented. We hereby report a case illustrating the use of botulinum A toxin in a 14- year-old girl with disabling axillary hyperhydrosis.展开更多
Objective: To investigate whether the volume of solution used to inject equiv alent units of botulinum exotoxin A affects the diffusion of toxin and areas of rhytid diminution in the treatment of dynamic forehead line...Objective: To investigate whether the volume of solution used to inject equiv alent units of botulinum exotoxin A affects the diffusion of toxin and areas of rhytid diminution in the treatment of dynamic forehead lines. Design: Ten volunt eers with dynamic forehead lines were included. Each study patient received a si ngle injection at a point 2.5 cm above the orbital rim on either side of the for ehead with equivalent units, but in different volumes, of botulinum exotoxin A. The sides of injection were randomized; one side of the patient’s forehead was injected first with 5 U of botulinum exotoxin A in 0.25 mL (2 U/0.1 mL) of pres erved saline in the midpupillary line, followed by injection of the other side w ith 5 U in 0.05 mL of preserved saline (2U/0.02mL). Therewas a 5- fold difference in volume injected. Subjects were evaluated 14 days later for total area affected during visual inspection of the subjects’foreheads during active muscle contraction. Setting: Private dermat ology office. Main Outcome Measure: Visual inspection to measure the area of rhy tid effacement in both height and width. Results: The area affected by the botul inum exotoxin A injection was 50% greater in the side with the larger volume i n 9 of 10 subjects. The average area affected was 6.05 cm2 for the injection of the larger volume compared with 4.12 cm2 for the injection with the smaller volu me. The shape of rhytid effacement was oval, rather than round, with the average width longer than the average height. Conclusions: In this prospective, randomi zed, controlled study, we found that injection of botulinum exotoxin A in low co ncentration and higher volume resulted in greater diffusion and a larger affecte d area. The pattern of toxin spread is altered by muscular contraction in the in jected sites. These results show that the dilution has implications on the desir ed effect of botulinum exotoxin A.展开更多
目的:探讨眼睑局部注射A型肉毒杆菌对于眼睑痉挛的效果。方法:收集2022年7月~2024年2月被我院确诊为特发性眼睑痉挛的患者资料,筛选出其中符合条件者共78例作为研究对象。所有受试者均给予眼睑局部多点A型肉毒杆菌毒素治疗。本次研究中...目的:探讨眼睑局部注射A型肉毒杆菌对于眼睑痉挛的效果。方法:收集2022年7月~2024年2月被我院确诊为特发性眼睑痉挛的患者资料,筛选出其中符合条件者共78例作为研究对象。所有受试者均给予眼睑局部多点A型肉毒杆菌毒素治疗。本次研究中,选取的观察指标包括药疗效果、维持时间与不良反应。结果:A型肉毒杆菌毒素眼睑局部注射后,观察到痉挛症状大多1~7天完全缓解,有效治疗率约为98.7%。药物疗效大多可以维持3~6个月左右,并且并发症少。结论:A型肉毒杆菌毒素对于特发性眼睑痉挛患者进行眼睑局部注射治疗效果显著而且副作用少见,值得在临床上推广使用。Objective: To investigate the effect of local injection of Botulinum Toxin Type A into eyelid for blepharospasm. Methods: Data of patients diagnosed with idiopathic blepharospasm in our hospital from July 2022 to February 2024 were collected, and a total of 78 eligible patients were selected as research objects. All subjects were treated with local eyelid multipoint Botulinum Toxin Type A. In this study, the observational indicators included therapeutic effect, maintenance time and adverse reactions. Results: The symptoms of spasmodic were completely relieved in 1~7 days with an effective rate of 98.7%. The effect usually lasts for 3~6 mouths with few complications. Conclusion: Botulinum Toxin Type A given by local injection on multiple sites is more effective than acupuncture and moxibustion in the treatment of idiopathic ocular and facial spasmodic.展开更多
近年来,A型肉毒杆菌毒素(botulinum toxin type A,BTXA)在瘢痕的治疗中引起了广泛的讨论和关注,本综述旨在讨论近5年以来国内外学者对BTXA在各类瘢痕防治中的应用及研究。其中,BTXA在术后瘢痕的应用最为普遍,术后早期、更高剂量的注射...近年来,A型肉毒杆菌毒素(botulinum toxin type A,BTXA)在瘢痕的治疗中引起了广泛的讨论和关注,本综述旨在讨论近5年以来国内外学者对BTXA在各类瘢痕防治中的应用及研究。其中,BTXA在术后瘢痕的应用最为普遍,术后早期、更高剂量的注射方法能达到更好的疗效。BTXA对瘢痕疙瘩、增生性瘢痕具一定的治疗潜力,联合其他治疗方法能达到更好的治疗效果,其最常与局部皮质类固醇注射联合,及与微针、二氧化碳点阵激光、光动力联合治疗。总体而言,BTXA对各类瘢痕的疗效良好,不良反应少,但作用机制尚不明确,仍需进一步研究。展开更多
目的:评价A型肉毒杆菌毒素(BTX-A)尿道外括约肌注射加巴氯芬口服治疗脊髓损伤后尿道外括约肌协同失调症(DESD)的临床效果。方法:尿流动力学检查证实脊髓损伤后DESD患者38例,男31例、女7例,平均年龄(36.5±17.8)岁。200 U BTX-A溶解...目的:评价A型肉毒杆菌毒素(BTX-A)尿道外括约肌注射加巴氯芬口服治疗脊髓损伤后尿道外括约肌协同失调症(DESD)的临床效果。方法:尿流动力学检查证实脊髓损伤后DESD患者38例,男31例、女7例,平均年龄(36.5±17.8)岁。200 U BTX-A溶解于8 ml生理盐水,使用尿道镜注射针分8点二平面注射于尿道外括约肌(1 ml/点)。术后第2日,随机选取12例患者(BTX-A+巴氯芬组)加服巴氯芬10 mg/次、3次/d,服用3个月,与另外26例患者作比较(BTX-A组)。4周后复查尿流动力学,随访2～9个月,比较治疗前后排尿症状、尿动力学检查结果的变化,并观察毒副作用。结果:治疗后1个月,膀胱贮尿和排尿功能有不同程度改善,最大尿流率、单次尿量、最大膀胱测压容积、膀胱顺应性增加,剩余尿量及充盈末逼尿肌压力下降,差异均有统计学意义(P<0.05)。BTX-A+巴氯芬组患者症状改善程度及膀胱顺应性明显优于单纯BTX-A组(P<0.05)。BTX-A+巴氯芬组有3例患者因出现神经系统不良反应而停药,其余患者无明显不良反应发生。结论:BTX-A注射加巴氯芬口服可以有效改善脊髓损伤后逼尿肌尿道外括约肌协同失调症患者的排尿障碍,长期疗效尚需进一步的随访观察。展开更多
为提高痉挛型脑性瘫痪(spastic cerebral palsy, SCP)患儿的运动功能,我们于1999年6月-2003年2月用A型肉毒杆菌毒素(botulinum toxin type A, BTX-A)痉挛肌肉局部注射结合针灸推拿治疗SCP患儿13例,并与单用BTX-A痉挛肌肉局部注射(18例)...为提高痉挛型脑性瘫痪(spastic cerebral palsy, SCP)患儿的运动功能,我们于1999年6月-2003年2月用A型肉毒杆菌毒素(botulinum toxin type A, BTX-A)痉挛肌肉局部注射结合针灸推拿治疗SCP患儿13例,并与单用BTX-A痉挛肌肉局部注射(18例)和单用针灸推拿(17例)治疗的患儿作对照,现将结果报告如下.展开更多
文摘Hyperhidrosis is an idiopathic condition of exaggerated sweat production by the eccrine glands that affects approximately 1% of the population. There are many viable therapeutic options and the use of botulinum toxin has become an important treatment option and received FDA approval for this disorder in July 2004. The other forms of aberrant sweating; bromhidrosis (malodorous) and chromhidrosis (pigmented) are much rarer and more recalcitrant to treatment. This is the first case report of dark-colored facial sweat in a young woman that was adequately controlled with botulinum toxin. Chromhidrosis is an unusual clinical entity with an ill defined glandular etiology. The successful response to botulinum toxin supports the eccrine gland as a source of the sweat production and, furthermore, that the administration of this toxin should be considered as a form of therapy.
文摘Axillary hyperhydrosis in children and teenagers may be severe enough to affect social development. Current treatments range from aluminum chloride compounds to surgical removal of sweat glands and sympathectomy. Intradermal injection of botulinum A toxin has recently been found to be a safe and effective alternative in the adult population. Use in children has so far not been documented. We hereby report a case illustrating the use of botulinum A toxin in a 14- year-old girl with disabling axillary hyperhydrosis.
文摘Objective: To investigate whether the volume of solution used to inject equiv alent units of botulinum exotoxin A affects the diffusion of toxin and areas of rhytid diminution in the treatment of dynamic forehead lines. Design: Ten volunt eers with dynamic forehead lines were included. Each study patient received a si ngle injection at a point 2.5 cm above the orbital rim on either side of the for ehead with equivalent units, but in different volumes, of botulinum exotoxin A. The sides of injection were randomized; one side of the patient’s forehead was injected first with 5 U of botulinum exotoxin A in 0.25 mL (2 U/0.1 mL) of pres erved saline in the midpupillary line, followed by injection of the other side w ith 5 U in 0.05 mL of preserved saline (2U/0.02mL). Therewas a 5- fold difference in volume injected. Subjects were evaluated 14 days later for total area affected during visual inspection of the subjects’foreheads during active muscle contraction. Setting: Private dermat ology office. Main Outcome Measure: Visual inspection to measure the area of rhy tid effacement in both height and width. Results: The area affected by the botul inum exotoxin A injection was 50% greater in the side with the larger volume i n 9 of 10 subjects. The average area affected was 6.05 cm2 for the injection of the larger volume compared with 4.12 cm2 for the injection with the smaller volu me. The shape of rhytid effacement was oval, rather than round, with the average width longer than the average height. Conclusions: In this prospective, randomi zed, controlled study, we found that injection of botulinum exotoxin A in low co ncentration and higher volume resulted in greater diffusion and a larger affecte d area. The pattern of toxin spread is altered by muscular contraction in the in jected sites. These results show that the dilution has implications on the desir ed effect of botulinum exotoxin A.
文摘目的:探讨眼睑局部注射A型肉毒杆菌对于眼睑痉挛的效果。方法:收集2022年7月~2024年2月被我院确诊为特发性眼睑痉挛的患者资料,筛选出其中符合条件者共78例作为研究对象。所有受试者均给予眼睑局部多点A型肉毒杆菌毒素治疗。本次研究中,选取的观察指标包括药疗效果、维持时间与不良反应。结果:A型肉毒杆菌毒素眼睑局部注射后,观察到痉挛症状大多1~7天完全缓解,有效治疗率约为98.7%。药物疗效大多可以维持3~6个月左右,并且并发症少。结论:A型肉毒杆菌毒素对于特发性眼睑痉挛患者进行眼睑局部注射治疗效果显著而且副作用少见,值得在临床上推广使用。Objective: To investigate the effect of local injection of Botulinum Toxin Type A into eyelid for blepharospasm. Methods: Data of patients diagnosed with idiopathic blepharospasm in our hospital from July 2022 to February 2024 were collected, and a total of 78 eligible patients were selected as research objects. All subjects were treated with local eyelid multipoint Botulinum Toxin Type A. In this study, the observational indicators included therapeutic effect, maintenance time and adverse reactions. Results: The symptoms of spasmodic were completely relieved in 1~7 days with an effective rate of 98.7%. The effect usually lasts for 3~6 mouths with few complications. Conclusion: Botulinum Toxin Type A given by local injection on multiple sites is more effective than acupuncture and moxibustion in the treatment of idiopathic ocular and facial spasmodic.
文摘近年来,A型肉毒杆菌毒素(botulinum toxin type A,BTXA)在瘢痕的治疗中引起了广泛的讨论和关注,本综述旨在讨论近5年以来国内外学者对BTXA在各类瘢痕防治中的应用及研究。其中,BTXA在术后瘢痕的应用最为普遍,术后早期、更高剂量的注射方法能达到更好的疗效。BTXA对瘢痕疙瘩、增生性瘢痕具一定的治疗潜力,联合其他治疗方法能达到更好的治疗效果,其最常与局部皮质类固醇注射联合,及与微针、二氧化碳点阵激光、光动力联合治疗。总体而言,BTXA对各类瘢痕的疗效良好,不良反应少,但作用机制尚不明确,仍需进一步研究。
文摘为提高痉挛型脑性瘫痪(spastic cerebral palsy, SCP)患儿的运动功能,我们于1999年6月-2003年2月用A型肉毒杆菌毒素(botulinum toxin type A, BTX-A)痉挛肌肉局部注射结合针灸推拿治疗SCP患儿13例,并与单用BTX-A痉挛肌肉局部注射(18例)和单用针灸推拿(17例)治疗的患儿作对照,现将结果报告如下.
